Affirmed Therapeutics BV (NASDAQ:AFMD) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) have been given a consensus rating of “Buy” by the seven brokerages that are covering the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $11.00.
AFMD has been the subject of a number of research analyst reports. Leerink Swann lowered shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $8.00 to $3.00 in a research note on Friday, August 12th. Jefferies Group restated a “hold” rating on shares of Affirmed Therapeutics BV in a research note on Tuesday, August 9th.
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) traded down 0.40% during mid-day trading on Monday, reaching $2.46. 58,850 shares of the company were exchanged. Affirmed Therapeutics BV has a 12 month low of $2.34 and a 12 month high of $8.42. The firm’s market capitalization is $82.38 million. The company’s 50-day moving average is $2.74 and its 200 day moving average is $3.23.
Affirmed Therapeutics BV (NASDAQ:AFMD) last posted its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. Affirmed Therapeutics BV had a negative net margin of 440.97% and a negative return on equity of 49.84%. The company’s revenue for the quarter was down 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) EPS. Analysts predict that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Affirmed Therapeutics BV by 6.8% in the first quarter. Geode Capital Management LLC now owns 29,204 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,856 shares in the last quarter. Paloma Partners Management Co acquired a new position in Affirmed Therapeutics BV during the second quarter worth approximately $142,000. Moore Capital Management LP acquired a new position in Affirmed Therapeutics BV during the first quarter worth approximately $281,000. BlackRock Institutional Trust Company N.A. increased its position in Affirmed Therapeutics BV by 1.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 108,911 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 1,713 shares in the last quarter. Finally, State Street Corp increased its position in Affirmed Therapeutics BV by 7.7% in the first quarter. State Street Corp now owns 220,885 shares of the biopharmaceutical company’s stock worth $823,000 after buying an additional 15,714 shares in the last quarter. 42.86% of the stock is owned by hedge funds and other institutional investors.
Affirmed Therapeutics BV Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related companies with MarketBeat.com's FREE daily email newsletter.